New Zealand markets closed
  • NZX 50

    10,753.16
    -115.54 (-1.06%)
     
  • NZD/USD

    0.6162
    -0.0083 (-1.32%)
     
  • NZD/EUR

    0.5905
    -0.0048 (-0.80%)
     
  • ALL ORDS

    6,720.40
    -26.10 (-0.39%)
     
  • ASX 200

    6,539.90
    -28.20 (-0.43%)
     
  • OIL

    108.69
    +2.93 (+2.77%)
     
  • GOLD

    1,787.60
    -19.70 (-1.09%)
     
  • NASDAQ

    11,503.72
    -154.55 (-1.33%)
     
  • FTSE

    7,149.65
    -19.63 (-0.27%)
     
  • Dow Jones

    30,775.43
    -253.88 (-0.82%)
     
  • DAX

    12,755.17
    -28.60 (-0.22%)
     
  • Hang Seng

    21,859.79
    -137.10 (-0.62%)
     
  • NIKKEI 225

    25,935.62
    -457.42 (-1.73%)
     
  • NZD/JPY

    83.3820
    -1.3330 (-1.57%)
     

What Is Ingevity Corporation's (NYSE:NGVT) Share Price Doing?

·3-min read

Ingevity Corporation (NYSE:NGVT), might not be a large cap stock, but it led the NYSE gainers with a relatively large price hike in the past couple of weeks. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, could the stock still be trading at a relatively cheap price? Today I will analyse the most recent data on Ingevity’s outlook and valuation to see if the opportunity still exists.

Check out our latest analysis for Ingevity

What is Ingevity worth?

The share price seems sensible at the moment according to my price multiple model, where I compare the company's price-to-earnings ratio to the industry average. In this instance, I’ve used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock’s cash flows. I find that Ingevity’s ratio of 20.91x is trading slightly above its industry peers’ ratio of 17.22x, which means if you buy Ingevity today, you’d be paying a relatively reasonable price for it. And if you believe that Ingevity should be trading at this level in the long run, then there should only be a fairly immaterial downside vs other industry peers. Is there another opportunity to buy low in the future? Since Ingevity’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

What kind of growth will Ingevity generate?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Ingevity's earnings over the next few years are expected to increase by 98%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? It seems like the market has already priced in NGVT’s positive outlook, with shares trading around industry price multiples. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at NGVT? Will you have enough conviction to buy should the price fluctuate below the industry PE ratio?

Are you a potential investor? If you’ve been keeping an eye on NGVT, now may not be the most advantageous time to buy, given it is trading around industry price multiples. However, the optimistic forecast is encouraging for NGVT, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

If you'd like to know more about Ingevity as a business, it's important to be aware of any risks it's facing. You'd be interested to know, that we found 3 warning signs for Ingevity and you'll want to know about them.

If you are no longer interested in Ingevity, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting